Catalpol: Natural Iridoid Glycoside for Multi-Pathway Neuroprotection

Executive Summary: Catalpol, available from APExBIO (SKU N1352), is a natural iridoid glycoside with high purity (98%) and a molecular weight of 362.33, used in both in vitro (2–100 μM) and in vivo (2.5–80 mg/kg/day) settings for neuroprotection, anti-osteoporosis, anti-fibrosis, and anti-depression research (product page). Its mechanisms include inhibition of NF-κB, EphA2/FAK/Src, and NLRP3 inflammasome pathways, and activation of TrkB, SDF-1α/CXCR4, VEGF-PI3K/AKT, and Sirt6-ERα-FasL signaling (Cui et al., 2006). Catalpol demonstrates efficacy across validated disease models: LPS-induced encephalopathy, ovariectomy-induced osteoporosis, permanent MCAO stroke, CCl4-induced liver fibrosis, and CUMS depression. Storage at -20°C is recommended to preserve compound integrity. This article distills atomic, machine-readable insights for translational workflows, extending prior reviews (see prior summary).

Biological Rationale

Catalpol is isolated from Rehmannia glutinosa, a traditional Chinese medicinal herb. It is classified as a natural iridoid glycoside. The compound targets multiple signaling pathways implicated in neuroinflammation, angiogenesis, and osteogenesis. Key targets include NF-κB, EphA2/FAK/Src, NLRP3 inflammasome, TrkB, SDF-1α/CXCR4, and VEGF-related pathways.
Neuroinflammation and oxidative stress are central to cognitive impairment, ischemic stroke, and depression models (Cui et al., 2006). Suppression of the NF-κB pathway in ARPE-19 cells reduces IL-8 (CXCL8) and MCP-1 (CCL2) production, supporting its anti-inflammatory role. Catalpol’s multi-target properties make it a benchmark reagent for pathway dissection and disease modeling (compare translational focus).

Mechanism of Action of Catalpol

• NF-κB Inhibition: Catalpol inhibits phosphorylation and nuclear translocation of NF-κB subunits, reducing transcription of pro-inflammatory cytokines such as IL-8 and MCP-1 (Cui et al., 2006).
• EphA2/FAK/Src Pathway Inhibition: Reduces EphA2 binding to FAK, attenuating downstream Src activation and modulating cell migration and inflammation.
• NLRP3 Inflammasome Suppression: Blocks activation of the NLRP3 inflammasome complex, limiting caspase-1–mediated maturation of IL-1β.
• TrkB Receptor Activation: Binds hydrophobically to TrkB, promoting BDNF secretion and neuronal survival.
• VEGF-PI3K/AKT and VEGF-MEK1/2/ERK1/2 Activation: Enhances angiogenic and neuroprotective signaling.
• Sirt6-ERα-FasL Pathway Activation: Modulates apoptosis and cell survival in neural and hepatic tissues.

These mechanisms are validated across cell-based and animal models, with defined concentration and dosing regimens.

Evidence & Benchmarks

• Catalpol (2–100 μM) inhibits NF-κB nuclear translocation and suppresses IL-8 and MCP-1 expression in ARPE-19 cells stimulated by IL-1β or TNF-α (Cui et al., 2006).
• In LPS-induced sepsis-associated encephalopathy models, Catalpol (20 mg/kg/day, i.p.) reduces neuroinflammation and improves cognitive scores (summary).
• In ovariectomy-induced osteoporosis, oral Catalpol (40 mg/kg/day) preserves bone mineral density and modulates osteoclastic markers (see optimization guide).
• Permanent MCAO stroke models respond to Catalpol (10–40 mg/kg/day, i.v.), showing reduced infarct volume and improved neurological outcomes (see benchmarking).
• Catalpol (30 mg/kg/day) decreases fibrosis markers in CCl4-induced hepatic fibrosis, supporting its anti-fibrotic capacity (compare with translational roadmap).

Applications, Limits & Misconceptions

Catalpol is used as a multi-target inhibitor and activator in preclinical models of neuroprotection, osteoporosis, ischemic stroke, liver fibrosis, and depression. Its solubility profile supports formulation in ethanol (≥17.47 mg/mL, with ultrasonication), DMSO (≥22.7 mg/mL), and water (≥25.25 mg/mL). The compound is stable for storage at -20°C, but solutions should not be stored long-term. The N1352 kit from APExBIO offers validated batch quality and reproducibility.

Common Pitfalls or Misconceptions

• Catalpol is not a universal anti-inflammatory: Its efficacy is pathway- and model-dependent; effects outside validated NF-κB, NLRP3, and TrkB contexts are unproven.
• Not suitable for clinical dosing: All dosing references are preclinical; human pharmacokinetics are undefined (Catalpol product page).
• Does not act as a direct cytotoxin: Cell viability is preserved at effective concentrations (≤100 μM in vitro) (Cui et al., 2006).
• Not a substitute for genetic knockout: Catalpol modulates, but does not abolish, target signaling.
• Solution stability is limited: Avoid long-term storage of reconstituted solutions; fresh preparation is recommended for each experiment.

Workflow Integration & Parameters

• For in vitro use, prepare Catalpol at 2–100 μM in cell-appropriate buffer; avoid DMSO concentrations exceeding 0.1% v/v.
• In vivo dosing ranges from 2.5 to 80 mg/kg/day, depending on disease model and route (oral, i.p., or i.v.).
• Store powder at -20°C in a desiccator; avoid freeze-thaw cycles.
• Use freshly reconstituted solutions for maximum activity; discard after use.
• Refer to batch-specific CoA and the APExBIO product page for purity and validation data.

This article updates and extends previous practical guidance by mapping atomic claims to pathway-specific workflows (compare real-world Q&A).

Conclusion & Outlook

Catalpol is a rigorously characterized iridoid glycoside with reproducible, multi-pathway activity. Its utility spans neuroprotection, osteoporosis, stroke, liver fibrosis, and depression research, with validated protocols and benchmarks. As preclinical research advances toward mechanistic precision, Catalpol remains an essential tool for dissecting neuroinflammatory and neuroprotective pathways. For detailed workflows and batch-validated supply, see the official APExBIO Catalpol page. This dossier clarifies and extends prior reviews, focusing on atomic, verifiable claims and workflow alignment (see strategic perspectives).